We evaluated the impact of irAE-prone anti-CTLA-4 antibody Ipilimumab in cells with ectopic expression of CTLA-4 by both immunoblot and by flow cytometry. A potential caveat in measuring antibody-induced CTLA-4 downregulation is CTLA-4 masking by pre-existing antibodies, although no such caveats...